市場調査レポート
商品コード
1410826
EGFR検査市場:市場規模(セグメント別)、シェア、規制、償還、予測(~2033年)EGFR Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 |
● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。 詳細はお問い合わせください。
EGFR検査市場:市場規模(セグメント別)、シェア、規制、償還、予測(~2033年) |
出版日: 2023年12月14日
発行: GlobalData
ページ情報: 英文
納期: 即納可能
|
世界的に、肺がんは男性で2番目に多いがんであり、女性では3番目に多いがんです。二次情報によると、2018年に世界で新たに報告された肺がん症例はおよそ200万人です。喫煙は、すべての年齢層で肺がんに関連する支配的な危険因子であり、世界の肺がん症例の男性の約80%、女性の約45%が喫煙に起因しています。
EGFRは受容体チロシンキナーゼファミリーの一員であり、細胞増殖、浸潤、転移、血管新生、アポトーシスの抑制を制御する主要因子です。EGFRはNSCLCにおいて最も日常的に検査されるバイオマーカーの一つです。
腺がんで見られるEGFR変異のほとんどはチロシンキナーゼドメインに位置しています。最も頻繁に遭遇する変異はエクソン19のインフレーム欠失(約45%)とエクソン21の点変異(L858R)で、これらを合わせると記載されている変異の85%以上を占めています。これらの変異は、チロシンキナーゼ阻害剤(TKI)であるゲフィチニブ、エルロチニブ、アファチニブ、イコチニブなどのEGFR治療が奏効するNSCLC患者と強く相関しています。
当レポートは、世界のEGFR検査市場について詳細に考察し、市場における競合情勢、SWOT分析、2033年までの市場予測、COVID-19の影響、地域、国別の動向などを提供しています。
Not Applicable
Not Applicable
EGFR Tests Market Size by Segments, Share, Regulatory, Reimbursement, and Forecast to 2033 is built to visualize quantitative market trends within In Vitro Diagnostics therapeutic area.
The model discusses in detail the impact of COVID-19 on EGFR Tests market for the year 2020 and beyond. Globally, lung cancer is the second most common cancer in men and the third most common cancer in women. Secondary sources estimate that approximately 2.0 million new cases of lung cancer were reported worldwide in 2018. Cigarette smoking is the dominant risk factor associated with lung cancer across all age groups, with approximately 80% of male and 45% of female lung cancer cases worldwide attributed to smoking.
EGFR is a member of the receptor tyrosine kinase family and a major factor in regulating cellular proliferation, invasion, metastasis, angiogenesis, and inhibition of apoptosis. EGFR is one of the most routinely tested biomarker in NSCLC.
Most EGFR mutations found in adenocarcinoma are located in the tyrosine kinase domain. The most frequently encountered mutations are in-frame deletions in exon 19 (around 45%) and a point mutation in exon 21 (L858R), which together account for over 85% of described mutations. These mutations strongly correlate with NSCLC patients responding to EGFR therapies such as the tyrosine kinase inhibitors (TKIs) gefitinib, erlotinib, afatinib, and icotinib.
The model includes EGFR Immunohistochemistry Tests, EGFR Sanger Sequencing Tests, EGFR Nucleic Acid Amplification Tests (NAATs), and EGFR Other Tests (EGFR ISH and Mass Array tests).
Each of the covered 39 country's color-coded and fully-sourced market models are equipped with epidemiology based indications with procedure volumes. To increase the data transparency, the interactive excel deliverable covers installed base, new sales volumes, product usage, average selling prices, market size and company share/rank analysis (wherever available). Moreover, analyst comments with qualitative insight offer context for quantitative data.
Key Inclusions of the market model are:
Currently marketed EGFR Tests and evolving competitive landscape:
Global, Regional and Country level market specific insights:
Drive the understanding of the market by getting the veritable big picture including an overview of the healthcare system. In addition, the Market Access segment allows you to delve deeper into market dynamics with information on reimbursement policies and the regulatory landscape.
Robust methodologies and sources enable the model to provide extensive and accurate overview of the market. Demand and supply-side primary sources are integrated within the syndicated models, including Key Opinion Leaders. In addition, real world data sources are leveraged to determine market trends; these include government procedure databases, hospital purchasing databases, and proprietary online databases.
Companies covered: F. Hoffmann-La Roche Ltd, Qiagen NV, Agilent Technologies Inc, Illumina Inc, Thermo Fisher Scientific Inc, Abbott Laboratories, NimaGen BV, Mesa Laboratories Inc, New England Biolabs Inc, Amoy Diagnostics Co Ltd, HLB PanaGene Co Ltd, and others.
Countries covered: United States, United Kingdom, Germany, France, Italy, Spain, Brazil, China, India, Russia, Japan, Australia, Canada, Mexico, South Korea, Denmark, Ireland, Netherlands, New Zealand, South Africa, Sweden, Switzerland, Austria, Belgium, Finland, Israel, Norway, Poland, Portugal, Taiwan, Czech Republic, Greece, Hungary, Turkey, Egypt, Saudi Arabia, United Arab Emirates, Argentina, and Chile.
This Market Model gives important, expert insight you won't find in any other source. The model illustrates qualitative and quantitative trends within the specified market. This model is required reading for -
The model will enable you to -
Not Applicable